When can darolutamide (Nubeqa) be restarted after the absolute neutrophil count recovers to ≥1.5 × 10⁹/L and the patient has been afebrile for at least 24 hours?

When to Restart Darolutamide After Neutrophil Recovery

Restart darolutamide at a reduced dose of 300 mg twice daily when the absolute neutrophil count (ANC) recovers to >1000/µL in afebrile patients, or when the ANC returns to baseline levels after a Grade ≥3 neutropenic event. 1

Dosing Algorithm Based on Neutrophil Recovery

The FDA-approved darolutamide label provides clear guidance for restarting therapy after hematologic toxicity 1:

For Grade ≥3 Adverse Reactions (Including Severe Neutropenia):

• Withhold darolutamide until symptoms improve and the adverse reaction returns to baseline
• Resume at 300 mg twice daily (reduced from the standard 600 mg twice daily dose)
• May attempt re-escalation to 600 mg twice daily if tolerated, though the label does not mandate this
• Do not reduce below 300 mg twice daily - this is the minimum effective dose 1

Specific Neutropenia Management Context:

Recent expert consensus guidelines for prostate cancer patients on novel hormonal therapy provide additional granularity 2:

For ANC 501-1000/µL without fever:

• Hold therapy temporarily
• Restart when white count recovers
• Consider reduced dosing if fever develops or ANC predicted to fall below 500/µL in next 48 hours

For ANC >1000/µL but below normal:

• Individualize based on clinical circumstances
• Hold temporarily only if patient is febrile or has evidence of infection

Critical Clinical Considerations

Timing of Restart:

The 24-hour afebrile requirement mentioned in your question aligns with standard neutropenic fever management principles 3, though the darolutamide label itself does not specify this exact timeframe. In practice, ensure the patient has been afebrile for at least 24 hours AND has documented ANC recovery before restarting.

Common Pitfalls to Avoid:

1. Do not restart at full dose (600 mg twice daily) immediately after Grade ≥3 neutropenia - the label explicitly recommends dose reduction to 300 mg twice daily 1
2. Do not continue dose reduction below 300 mg twice daily - this is ineffective and not recommended
3. Consider permanent discontinuation if persistent severe neutropenia (ANC 501-1000 or <500/µL) occurs despite dose modifications 2

Special Populations:

In older adults (≥80 years), neutrophil recovery time may be significantly prolonged 4. Monitor these patients more closely and be prepared for longer treatment interruptions, though PSA response rates remain comparable across age groups.

Combination Therapy Context:

If darolutamide is being used with docetaxel (as in metastatic hormone-sensitive prostate cancer), treatment with darolutamide may continue even if docetaxel cycles are delayed or discontinued due to neutropenia 1. The two agents can be managed independently for hematologic toxicity.